原发性醛固酮增多症慢性肾损伤的研究进展

doi:10.16138/j.1673-6087.2023.03.016

摘要/Abstract

中图分类号:

R586.24

赖莉琴, 龚艳春. 原发性醛固酮增多症慢性肾损伤的研究进展[J]. 内科理论与实践, 2023, 18(03): 211-214.

LAI Liqin, GONG Yanchun. Research progress of chronic kidney injury in primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 211-214.

参考文献 40

[1]	Funder JW, Carey RM. Primary aldosteronism: where are we now? Where to from here?[J]. Hypertension, 2022, 79(4): 726-735. doi: 10.1161/HYPERTENSIONAHA.121.18761 URL
[2]	国家卫生健康委高血压诊疗研究重点实验室学术委员会. 高血压患者中原发性醛固酮增多症检出、诊断和治疗的指导意见[J]. 中华高血压杂志, 2021, 29(6): 508-518.
[3]	Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16): 1913-1922. doi: S0735-1097(20)34459-4 pmid: 32327102
[4]	Shrestha A, Che RC, Zhang AH. Role of aldosterone in renal fibrosis[J]. Adv Exp Med Biol, 2019, 1165: 325-346. doi: 10.1007/978-981-13-8871-2_15 pmid: 31399972
[5]	Han HI, Skvarca LB, Espiritu EB, et al. The role of macrophages during acute kidney injury: destruction and repair[J]. Pediatr Nephrol, 2019, 34(4): 561-569. doi: 10.1007/s00467-017-3883-1 pmid: 29383444
[6]	Yuan X, Wang X, Li Y, et al. Aldosterone promotes renal interstitial fibrosis via the AIF-1/AKT/mTOR signaling pathway[J]. Mol Med Rep, 2019, 20(5): 4033-4044.
[7]	Barrera-Chimal J, Jaisser F. Vascular and inflammatory mineralocorticoid receptors in kidney disease[J]. Acta Physiol (Oxf), 2020, 228(2): e13390.
[8]	Barati A, Rahbar Saadat Y, et al. Eplerenone reduces renal ischaemia/reperfusion injury by modulating Klotho, NF-κB and SIRT1/SIRT3/PGC-1α signalling pathways[J]. J Pharm Pharmacol, 2022, 22: rgac054.
[9]	Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis[J]. Kidney Int Suppl (2011), 2022, 12(1):63-68.
[10]	Gifford CC, Lian F, Tang J, et al. PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of Klotho, p53, and TGF-β1-receptor signaling[J]. FASEB J, 2021, 35(7): e21725.
[11]	Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis[J]. Nat Rev Nephrol, 2013, 9(8): 459-69. doi: 10.1038/nrneph.2013.110 pmid: 23774812
[12]	Gifford CC, Tang J, Costello A, et al. Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities[J]. Clin Sci (Lond), 2021, 135(2): 275-303. doi: 10.1042/CS20201213 pmid: 33480423
[13]	银锡靖, 覃诗婷, 杨柯. 骨桥蛋白在肾纤维化不同阶段中的作用研究进展[J]. 山东医药, 2018, 58(7): 105-107.
[14]	Spencer S, Wheeler-Jones C, Elliott J. Aldosterone and the mineralocorticoid receptor in renal injury: a potential therapeutic target in feline chronic kidney disease[J]. J Vet Pharmacol Ther, 2020, 43(3): 243-267. doi: 10.1111/jvp.12848 pmid: 32128854
[15]	Hundemer GL, Curhan GC, Yozamp N, et al. Renal outcomes in medically and surgically treated primary aldosteronism[J]. Hypertension, 2018, 72(3): 658-666. doi: 10.1161/HYPERTENSIONAHA.118.11568 pmid: 29987110
[16]	Monticone S, Sconfienza E, D’Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis[J]. J Hypertens, 2020, 38(1): 3-12. doi: 10.1097/HJH.0000000000002216 pmid: 31385870
[17]	Hajji M, Rais L, Kheder R, et al. Primary aldosteronism diagnosed in a patient with severe renal disease[J]. Tunis Med, 2018, 96(7): 454-457.
[18]	Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension[J]. J Hypertens, 1995, 13(12 Pt 2):1801-1802. pmid: 8903655
[19]	Danforth DN Jr, Orlando MM, Bartter FC, et al. Renal changes in primary aldosteronism[J]. J Urol, 1977, 117(2): 140-144. doi: 10.1016/s0022-5347(17)58376-7 pmid: 833953
[20]	李南方, 马轩, 王红梅, 等. 原发性醛固酮增多症患者蛋白尿情况分析[J]. 中华高血压杂志, 2013, 21(3): 249-252.
[21]	Chebotareva N, Bobkova I, Lysenko L, et al. Urinary markers of podocyte dysfunction in chronic glomerulonephritis[J]. Adv Exp Med Biol, 2021, 1306: 81-99. doi: 10.1007/978-3-030-63908-2_6 pmid: 33959907
[22]	Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 487-500. doi: 10.1007/978-981-13-8871-2_24 pmid: 31399981
[23]	Fernández-Argüeso M, Pascual-Corrales E, Bengoa Rojano N, et al. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension[J]. Endocrine, 2021, 73(2): 439-446. doi: 10.1007/s12020-021-02704-2 pmid: 33797699
[24]	姬文娜, 崔巍. 原发性醛固酮增多症患者早期肾脏损害相关临床因素分析[J]. 延安大学学报(医学科学版), 2017, 15(4): 19-22.
[25]	Petramala L, Concistrè A, Circosta F, et al. Evaluation of intra-renal stiffness in patients with primary aldosteronism[J]. High Blood Press Cardiovasc Prev, 2022, 29(1): 49-56. doi: 10.1007/s40292-021-00485-3
[26]	Ogata H, Yamazaki Y, Tezuka Y, et al. Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary adosteronism[J]. Hypertension, 2021, 78(2): 411-421. doi: 10.1161/HYPERTENSIONAHA.121.17436 URL
[27]	Nakamura Y, Kobayashi H, Tanaka S, et al. Primary aldosteronism and obstructive sleep apnea[J]. Medicine (Baltimore), 2021, 100(11): e25049. doi: 10.1097/MD.0000000000025049 URL
[28]	Nakamura Y, Kobayashi H, Tanaka S, et al. Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism[J]. Clin Endocrinol (Oxf), 2021, 94(6): 920-926. doi: 10.1111/cen.v94.6 URL
[29]	Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism[J]. J Clin Endocrinol Metab, 2009, 94(3): 869-875. doi: 10.1210/jc.2008-1851 pmid: 19116235
[30]	Kawashima A, Sone M, Inagaki N, et al. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism[J]. Eur J Endocrinol, 2019, 181(3): 339-350. doi: 10.1530/EJE-19-0047 pmid: 31319380
[31]	Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management[J]. Endocrinol Metab Clin North Am, 2019, 48(4): 681-700. doi: 10.1016/j.ecl.2019.08.002 URL
[32]	Saiki A, Otsuki M, Tamada D, et al. Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin[J]. J Endocr Soc, 2021, 6(1): bvab174. doi: 10.1210/jendso/bvab174 URL
[33]	Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism[J]. Nat Rev Endocrinol, 2020, 16(10): 578-589. doi: 10.1038/s41574-020-0382-4
[34]	赵菁, 张进安. 原发性醛固酮增多症:一个常见的“罕见病”[J]. 上海医药, 2021, 42(8): 3-6.
[35]	Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases[J]. Drug Dev Res, 2021, 82(3): 341-363. doi: 10.1002/ddr.v82.3 URL
[36]	Chrissobolis S. Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism[J]. Curr Hypertens Rev, 2017, 13(1): 46-56. doi: 10.2174/1573402113666170228151402 pmid: 28245785
[37]	中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736.
[38]	Lechner B, Lechner K, Heinrich D, et al. Therapy of endocrine disease: medical treatment of primary aldosteronism[J]. Eur J Endocrinol, 2019, 181(4): R147-R153. doi: 10.1530/EJE-19-0215
[39]	Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research[J]. J Hypertens, 2020, 38(10): 1929-1936. doi: 10.1097/HJH.0000000000002520 pmid: 32890265
[40]	杨汉继, 郝娟, 张雨轩. 依普利酮通过下调VEGF表达抑制UUO模型大鼠对侧肾脏血管新生并减轻肾脏纤维化[J]. 中国病理生理杂志, 2021, 37(4): 688-695.

原发性醛固酮增多症慢性肾损伤的研究进展

Research progress of chronic kidney injury in primary aldosteronism

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	魏亚培　王婷婷　陈滢滢　张睿　郝昆. 胸导管探查术后综合消肿治疗对双下肢淋巴水肿患者的短期效果 [J]. 组织工程与重建外科杂志, 2023, 19(3): 249-.
[2]	管亚芩　吴锦阳　余丽雅　张诗雷. 数字化手术设计流程在颌面部骨折整复治疗中的应用分析 [J]. 组织工程与重建外科杂志, 2023, 19(3): 289-.
[3]	李新宇郭智霖. 外伤性视神经损伤的研究进展 [J]. 组织工程与重建外科杂志, 2023, 19(3): 315-.
[4]	邱煜程　周显玉　刘菲　杨军. 间充质干细胞及其外泌体在移植中的应用进展 [J]. 组织工程与重建外科杂志, 2023, 19(2): 184-.
[5]	孙家园　侯瑞　张如鸿. 缺血再灌注损伤性皮瓣坏死的防治进展 [J]. 组织工程与重建外科杂志, 2023, 19(2): 193-.
[6]	边巴拉吉　次旺加措　蔡磊　巴罗　周栩. 西藏地区保留局部皮瓣联合小剂量放疗治疗耳廓瘢痕疙瘩的临床研究 [J]. 组织工程与重建外科杂志, 2023, 19(1): 34-.
[7]	高定辉, 陈勇, 王倩, 等. 肌内静脉畸形的影像学观察：单中心回顾性分析 [J]. 组织工程与重建外科杂志, 2023, 19(1): 37-.
[8]	刘井清, 林燕娴, 袁巍巍, 等. 单次聚焦射频治疗皮肤型鼻唇沟凹陷的初步研究[J]. 组织工程与重建外科杂志, 2023, 19(1): 44-.
[9]	陈娅, 周慧. 血液肿瘤患者焦虑抑郁现状及与治疗信心的相关性研究[J]. 组织工程与重建外科杂志, 2023, 19(1): 59-.
[10]	邓智中, 周显玉, 刘菲, 等. 免疫抑制缓释用于治疗同种异体复合组织移植的研究进展[J]. 组织工程与重建外科杂志, 2023, 19(1): 79-.
[11]	张会健, 李贵森. IgA肾病补体靶向治疗研究进展[J]. 内科理论与实践, 2023, 18(03): 197-200.
[12]	邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[13]	高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅. 新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151.
[14]	王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[15]	徐凯, 李百文. 早期胃癌及胃癌前病变的内镜黏膜下剥离术治疗[J]. 内科理论与实践, 2023, 18(02): 102-106.